Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 8/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910773 | 1.00 | IDO1 (0.49) | IDO1AGXTMAOBGLAHCAR2 | |
| SCHEMBL5561672 | 0.88 | IDO1 (0.41) | IDO1AGXTMAOB | |
| SCHEMBL6651489 | 0.86 | TAAR1 (0.42) | IDO1AGXTMAOBGABRG2GABRB3 | |
| SCHEMBL1314001 | 0.84 | AGXT (0.42) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL8149467 | 0.84 | GABRA1 (0.41) | GABRG2GABRB3GABRA3TAAR1 | |
| SCHEMBL4587307 | 0.83 | IDO1 (0.42) | IDO1MAOB | |
| SCHEMBL3932476 | 0.83 | TACR1 (0.43) | — | |
| SCHEMBL5432748 | 0.82 | SIGMAR1 (0.40) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL8795972 | 0.82 | TSHR (0.34) | IDO1AGXTMAOB | |
| SCHEMBL8024443 | 0.82 | MRGPRX4 (0.38) | GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054724-A1 | BIFUNCTIONAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021086785-A1 | BIFUNCTIONAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-0649414-B1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | ARDENT PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0629604-B1 | Alicyclic phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0399818-B1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC (CA) | 1995-08-16 | — | — | EP | disclosed |
| US-5436369-A | Alicyclic phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| EP-0629604-A2 | Alicyclic phospholipase A2 inhibitors | Bristol-Myers Company (US) | 1994-12-21 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-5204358-A | Antiallergens; antiinflammatory agents; treatment of asthma, rhinitis, bronchitis and skin diseases | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
| EP-0318093-A2 | Diarylquinoline diacids and their use as medicaments | MERCK FROSST CANADA INC. (CA) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | IDO1 4063/4885AGXT 4573/4885MAOB 4337/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | IDO1 1202/4885AGXT 3447/4885MAOB 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.